Phillip A. Sharp

News + Videos

KI Collaborators Edit Genes to Correct Genetic Diseases

Using a new gene-editing system known as CRISPR to replace mutated DNA with the correct sequence, KI engineers and biologists from the Anderson, Jacks, and Sharp Laboratories have cured mice of a rare liver disorder caused by a single mutation in an enzyme needed to break down the amino acid tyrosine. This collaborative work, described in Nature Biotechnology, offers the first evidence that this technology can reverse disease symptoms in living animals. The team believes that recent advances in the delivery of nucleic acid therapeutics provide hope that CRISPR-mediated correction of genetic diseases may be translatable to humans. The research was funded by the National Cancer Institute, the National Institutes of Health, and the Marie D. and Pierre Casimir-Lambert Fund. more...

Biogen Idec Dedicates New Building to Phillip A. Sharp

On February 11, 2014, Biogen, now Biogen Idec, celebrated the return of its headquarters to Binney Street in Cambridge. When Biogen first opened in 1982, Kendall Square was almost deserted. Today, Kendall Square is a vibrant bioscience community clustered around MIT’s campus and densely populated by high-profile biotech companies, research institutes, and start-ups. Biogen Idec's ceremonies included the dedication of one of its new buildings to Biogen co-founder, KI faculty member and Institute Professor, Phillip A. Sharp. The honor couldn’t be more fitting: Sharp’s career, his startup Biogen, and MIT’s biotech community helped build Kendall Square and launch the area's unprecedented biotech revolution. The Koch Institute is proud to be a part of this legacy; over the last five years, KI faculty members have formed 18 new companies, many of which are located in Kendall Square.

Coinciding with this dedication, MIT News recently featured Sharp’s scientific career, his finding the perfect environment at MIT's Center for Cancer Research, and his contributions to usher in MIT's “golden age” of biology. more...

Sharp Calls for Increased Links between Discovery, Innovation, and Entrepreneurship

KI faculty member and Institute Professor Phillip A. Sharp, the AAAS President, echoed the KI’s emphasis on interdisciplinary research in his opening President’s Address at this year’s AAAS meeting in Chicago. “If discovery is to come to the aid of our great global challenges of climate change, poverty and disease,” Sharp said, “we have no choice but to become much better at linking discovery, innovation, and entrepreneurship.” Sharp himself is both scientist and entrepreneur; he has co-founded two companies, Biogen (now Biogen Idec) and Alnylam Pharmaceuticals, which build on his research developing therapeutic methods to switch genes on and off through RNA interference (RNAi). Sharp encouraged attendees to consider and foster links between biological, physical, computational and engineering sciences, which form “the blueprint for future innovation.” more...

Direction, Direction, Direction: Sharp Lab Discovers How Cells Read Genes Only in the Right Direction

KI member Phillip Sharp and his team have discovered how cells read their own DNA in the correct direction. In their Nature publication, the KI team describes for the first time how cells are able to halt the reading process when it goes in the wrong direction and thus avoid copying most of the non-protein-coding genes (so-called 'junk DNA'). more...

Cancer Treatment Challenges Symposium/Roundtable

At this May 6, 2013 event, cancer biologists, engineers, and clinicians gathered at the Koch Institute at MIT for an open discussion of the greatest challenges and most promising solutions in cancer care. Speakers included:

Phillip A. Sharp, Institute Professor, Koch Institute at MIT
Sangeeta N. Bhatia, John J. and Dorothy Wilson Professor of Health Sciences and Technology & Electrical Engineering and Computer Science, Koch Institute at MIT
K. Dane Wittrup, Carbon P. Dubbs Professor of Chemical Engineering and Bioengineering, Koch Institute at MIT
Michael B. Yaffe, David H. Koch Professor of Biology and Biological Engineering, Koch Institute at MIT
Catherine J. Wu, Associate Physician, Medical Oncology, Dana-Farber Cancer Institute
Jay S. Loeffler, Chief, Radiation Oncology, Massachusetts General Hospital
Matthew R. Smith, Director, Genitourinary Malignancies Program, Massachusetts General Hospital Cancer Center
Steven P. Balk, Staff Physician, Hematology/Oncology, Beth Israel Deaconess Medical Center Hear highlights from the discussion in the video below. The event also featured presentations by researchers working on existing Bridge Project teams: Christopher Love, Koch Institute at MIT, Hidde Ploegh, Whitehead Institute and Koch Institute at MIT, and Kai W. Wucherpfennig, Dana Farber Cancer Institute
Novel Immunotherapies Against Pancreatic Cancer Elazer Edelman, Institute of Medical Engineering and Sciences at MIT and Koch Institute at MIT and Jeffrey W. Clark, Massachusetts General Hospital
A Pancreatobiliary Chemotherapy Eluting Stent for Pancreatic Ductal Adenocarcinomas Rakesh K. Jain, Massachusetts General Hospital and Robert Langer, Koch Institute at MIT
Angiotensin Receptor Blockers (ARBs) as a Novel Approach to Improve Drug Delivery in the Treatment of Pancreatic Cancer Keith L. Ligon, Dana-Farber Cancer Institute and J. Christopher Love, Koch Institute at MIT
Single-Cell Functional, Genomic and Transcriptomic Analysis in Glioblastoma watch...

KI Researchers Named Fellows of the Inaugural Class of the AACR Academy

KI members Tyler Jacks, H. Robert Horvitz, Phillip Sharp, and Bob Weinberg have been elected as members of the inaugural class of Fellows of the AACR Academy, which recognizes and celebrates distinguished scientists whose stellar scientific contributions in cancer research have propelled significant innovation and progress against cancer. David Baltimore, a founding faculty member of the KI's predecessor, the MIT Center for Cancer Research, is also among the elected Fellows. The AACR Academy will be inducting its inaugural class of illustrious Fellows at the 2013 Annual Meeting this April. more...

A Sharp Eye on Kendall Square

Co-founder of Biogen, now Biogen Idec, KI member Phil Sharp opened the company's first US office in Kendall Square in 1983.  Three decades later, the perspectives of the MIT Institute Professor, Nobel Laureate, and biotech pioneer feature prominently in a recent news series exploring the neighborhood's evolution, from a traditional manufacturing district to an international center for life sciences, biotech and high-tech firms. In Professor Sharp's opinion, Kendall's innovation hub is just hitting its stride.

more...

Stand Up to Cancer Launches Pediatric Dream Team

The entertainment industry's most widely known effort to fight cancer raised $81M in September, including funds for a new pediatric cancer research “Dream Team.”  Overseen by a Scientific Advisory Committee, led by KI member Phillip Sharp, and the American Association for Cancer Researcht, SU2C supports several "Dream Teams" of researchers working to accelerate ground-breaking research and bring new treatments to patients as quickly as possible. Its Circulating Tumor Cell Chip Dream Team includes KI members Sangeeta Bhatia, Scott Manalis and Ram Saisekharan. more...

AAAS Named President-elect for 2013

KI member, Nobel Laureate, and Institute Professor Phillip Sharp has been named the 2013 President-elect of the American Association for the Advancement of Science (AAAS). He will begin the one year term in February 2013. The international organization is dedicated to advancing science around the world by serving as an educator, leader, spokesperson and professional association. more...

Targeted Cancer Drugs Improve

With a better understanding the complex inner workings of the cancer cell, KI scientists are learning how to make cancer drugs work more effectively in a larger number of patients. In two studies focusing on a promising class of drugs for lung cancer, researchers have pinpointed new drug targets that could enhance the drugs' activity. They hope a specific combination of cancer drugs will improve individual cancer treatment. more...

Graphic: Christine Daniloff

The power of 'convergence'

A new model for scientific research known as "convergence" offers the potential for revolutionary advances in biomedicine and other areas of science, according to a white paper issued today by 12 leading MIT researchers. The white paper, presented Tuesday morning at a forum hosted by the American Association for the Advancement of Science (AAAS), says that the United States should capitalize on the trend of convergence – which involves the merger of life, physical and engineering sciences – to foster the innovation necessary to meet the growing demand for accessible, affordable health care. more...

Phillip Sharp

KI member recieves AACR's Margaret Foti Award

Phillip Sharp receivee the fourth annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR 101st Annual Meeting 2010. This award recognizes an individual whose leadership and extraordinary achievements in or in support of cancer research have made a major impact on the field overall. more...

The Third Revolution in Cancer Research

Phillip A. Sharp, Institute Professor watch...

The Economist reports on medicine going digital

KI research is paving the way for a revolutionary convergence of engineering and biology. more...

Mapping new RNA expression changes in cancer cells

Published in Science, KI researcher define novel changes in 3'UTR and microRNAs in cancer cells. more...